NEW YORK, Nov. 27, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. will sponsor a webinar on the "Promise of Alpha Therapy". The discussion will be broadcast and can be accessed via the link http://www.veomed.com/grandrounds?gnr=871099 on November 30, 2012 at 3:00 PM and followed by questions and answers session from the audience. Participants will discuss their personal experience, both clinical and pre-clinical, with alpha particle immunotherapy platform-based drug candidates. The discussion is moderated by Dr. Rosemary Mazanet and participants include Dr. David Scheinberg, Chairman, and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center, Dr. Joseph Jurcic, Associate Attending Physician at Sloan-Kettering's Department of Leukemia and Dr. Steven Larson, Vice Chair for Research, Department of Radiology at Sloan Kettering.
The focus of the webinar is the use of alpha radioimmunotherapy in clinical trials and preclinical models. Dr. Scheinberg, who originated the idea of alpha immunotherapy, will discuss theoretical underpinnings of the approach and results of his preclinical experiments. Dr. Jurcic is currently treating acute myeloid leukemia (AML) patients in clinical trials with alpha immunotherapy drug candidates and he will present his experience and results. As a participant in clinical trials from the nuclear medicine side, Dr. Larson will provide a first-hand account on the ease of use and requirements for alpha immunotherapy. All participants will also offer their views on the future prospects of drugs based on this platform technology. The panel discussion to be broadcast on November 30 at 3:00 PM Eastern Time, questions for participants may be submitted via firstname.lastname@example.org or by phone, the details for which are as below:
Phone number: +1 (213) 493-0614
Access Code: 157-776-237
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.
For more information:
Visit our web site www.actiniumpharmaceuticals.comor contact:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
ProActive Capital Group, LLC
Tel: (646) 863-6341
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals, Inc.